Why People Are Losing Faith in Healthcare
TL;DR
Eli Lilly CEO Dave Ricks joins Scott Galloway to explain how GLP-1 drugs represent a paradigm shift in treating obesity and its downstream chronic diseases, while detailing the company's strategy to expand access through direct-to-consumer pricing and Medicaid partnerships.
🧬 The GLP-1 Breakthrough 3 insights
Near-universal efficacy changes treatment paradigms
Unlike typical medications that work inconsistently across populations, GLP-1 drugs like Zepbound produce weight loss in almost every patient while delivering immediate satisfaction rather than side effects.
Obesity treatment as fiscal policy imperative
With obesity driving 80% of healthcare costs and $1.4 trillion in annual spending, Ricks argues reducing obesity rates is the only viable path to lowering Medicare/Medicaid deficits.
Chronic disease prevention at scale
Treating obesity addresses over 200 downstream chronic conditions including diabetes and cardiovascular disease, potentially reversing declining life expectancy trends.
🧠Unexpected Therapeutic Applications 3 insights
Inflammation and pain management
Eli Lilly's triple-acting retatrutide demonstrated unprecedented pharmacological pain reduction for knee arthritis by targeting inflammatory pathways closely linked to obesity.
Addiction mitigation across dependencies
Phase 2 trials and clinical observations reveal GLP-1s significantly reduce alcohol consumption, smoking, and gambling urges by dampening hedonic reward pathways without eliminating pleasure.
Cancer risk reduction in long-term data
Observational studies indicate patients using GLP-1 drugs for diabetes management over 5-6 years show reduced rates of obesity-related cancers including colorectal and breast cancer.
đź’° Democratizing Access & Pricing 3 insights
Direct-to-consumer pricing bypasses middlemen
Lilly Direct offers Zepbound at $399—60% below launch pricing—while oral Fondeo starts at $159, bypassing pharmacy benefit managers to eliminate regressive pricing structures.
Medicaid expansion targets highest-need populations
Recent agreements with states like Mississippi—where 79% of adults are obese—provide Medicaid access by demonstrating ROI through reduced downstream hospitalization costs.
Manufacturing scale eliminates supply constraints
$50 billion invested in U.S. manufacturing capacity aims to resolve shortages and enable further price reductions through competition and economies of scale.
Bottom Line
Addressing America's healthcare crisis requires treating obesity as the root cause of chronic disease through mass GLP-1 adoption, necessitating continued price reductions and expanded Medicaid access to reach low-income populations who would benefit most.
More from The Prof G Pod (Scott Galloway)
View all
China Tests Ballistic Missile, Europe's AC Addiction, & China's AI Coding Challenger | China Decode
China demonstrates advancing military capabilities with a JL3 ballistic missile test while simultaneously deepening Europe's economic dependency through surging air conditioner exports during record heat waves, even as Chinese open-source AI models threaten to outcompete Western alternatives globally.
Rep. Jim Himes: America Is Losing Leverage in Iran
Representative Jim Himes argues that the recent U.S.-Iran memorandum represents a catastrophic surrender of American leverage, resulting from President Trump ignoring accurate intelligence that predicted regime stability while being influenced by Netanyahu's flattery and fantasies of easy victory.
Young People Are Giving Up on Adulthood | John Burn-Murdoch
Falling birth rates reflect a crisis in relationship formation among young people who cannot achieve the stability to couple up, driven by housing insecurity, the decline of economically viable men, and digital isolation—particularly acute in the English-speaking world where mental health has deteriorated fastest.
Hong Kong's AI Crackdown, Lululemon’s Marketing Backlash, and World Cup Fever | China Decode
This episode examines escalating US-China tech tensions, with JP Morgan and Goldman Sachs restricting Anthropic AI access in Hong Kong while Washington pressures ASML over alleged advanced chip equipment shipments to China. The hosts also analyze Lululemon's marketing crisis in China, where a culturally ambiguous drum triggered nationalist backlash despite potentially Chinese origins.